The five possible suitors circling around the high growth SRX are Cephalon., Roche, Sanofi, Genentech and Pfizer. All five have in common lower margin businesses versus very high SRX 80% gross margin business. All also have complementary chemotherapy drugs that work well in extending survival times by over 100% in many cases with the use of Sirtex Sir Spheres. AT 10x eps with growth between 70-100%, SRX wont be this low for very long. The PEG ratio of 10/70=.14 is the lowest of biotechs, as most biotechs sell at PEG ratios of 1-2. I am adding more shares as I did 2 weeks ago.My little opinion only after being in industry for over 30 yrs.Do your own work
the five suitors of srx
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $292.8K | 1.630M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7394560 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1260654 | 10 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |